multiple applications within a single jurisdiction as one member of the family. Normalized in this way, the 95 families represented a total of 240 single-nation and European Patent Office (EPO) members. We also identified 211 JDs published between the period from 2004 to the end of July 2008.
Temporal PMP disclosure trends
To determine whether PMP disclosures are a representative sample of biopharmaceutical disclosures, we compared the temporal filing and publishing trends for both. For PDs that disclosed PMPs, we found a decrease over time in the number of patent families, as represented by their priority dates (Fig. 1a) . The apparent dramatic decline in international patenting activity after 2003, as represented by the graph bars in their entirety, was the result of a relatively large number of South Korean (Korean) patent filings, many filed in [2002] [2003] . The majority of these were by Korean applicants and filed solely at the Korean Patent Office (KPO), and were thus single-member families. In contrast, most other families, with the exception of small numbers of single-member families in China, Japan or the United States, had an international dimension, with either two or more members or a Patent Cooperation Treaty (PCT) member. The lower parts of the split bars represents families with an international dimension. These show a more gradual decrease, or at best a stagnation, in international patenting activity.
To ascertain whether this temporal decline was representative of the biopharmaceutical product sector as a whole, we searched for PCT applications classified under code C07K14. This code represents a repertoire of bioactive, immunomodulatory and antigenic molecules derived from various organisms. These are fairly representative of, but not restricted to, biopharmaceuticals, and also include, for example, policymakers that academic research should bring essential goods to the market.
Disclosure of inventions in academia is mostly through peer-reviewed journal disclosures (JD), to a lesser extent through patent applications (patent disclosures, PD) and sometimes through both routes. We have analyzed here the relationships between PDs and JDs in academia and industry in order to gain insights into their roles in the development of biopharmaceuticals. Our objectives were to obtain information on inventive and disclosure activity by institution type (industrial or academic) and geography, and also to identify geographical filing preferences in the biopharmaceutical field. An important focus was the extent of academia's contribution to product development. To do this for the entire biopharmaceutical field would be an overwhelming task, as the content, specifications and claims of large volumes of publications would need to be extensively scrutinized to correlate PDs and JDs. We therefore chose an emerging sector of the biopharmaceutical industry as a model, namely recombinant therapeutic proteins produced by processes that use transgenic plants or plant cells as hosts-often referred to as plant-made pharmaceuticals 3 (PMPs). We used data from PDs and JDs filed or published over a five-year span to deduce temporal, institutional and geographical trends in knowledge dissemination and commercialization (see Box 1).
Total patent applications and papers disclosing PMPs
Ninety-five priority applications claiming one or more PMP molecules were filed during 2002-2006, therefore representing 95 patent families. Multiple application numbers within a single country are not unusual, especially in the United States with its unique system of continuation applications. We therefore normalized B iopharmaceutical product development is enabled by both industrial and academic inventors. Critical to such development are disclosures through papers in scientific journals and applications to patent offices for proprietary rights. Both forms of disclosure have global effects on the dissemination of knowledge, the scope of proprietary protection for inventions, and the commercialization of biopharmaceuticals. Patenting activity is a major indicator of the commercialization of inventions. Academic involvement in product development has been facilitated by the Bayh-Dole Act 1 in the United States and similar instruments of legislation elsewhere, which permit universities to gain a return on investment through protection and licensing out of their intellectual property. Industry inventors have a relatively straightforward task, which is to enhance a company's commercial position. The dynamics in academia are more complex; nevertheless, the bottom line is predominantly career enhancement through peer-reviewed publications 2 . Yet academics are increasingly becoming major players in product development, albeit indirectly. There is a rising trend, reflected in journal and patent publications, toward product-oriented translational research. This is driven by industry sponsorship of research as well as by major public funders who recognize the supply-demand gap for products targeted toward diseases neglected by traditional industry, by the need to generate licensing revenue, and by recognition from these assumptions together with data about inventor affiliation, we made an estimate of the origin of patented research from each institution type (Fig. 2a) . Of the 95 families, 58% originated from academic research and 27% from industrial research. A further 6% resulted from industry-academic collaboration. For the rest of the patents it was not possible to determine affiliation.
Only 2/39 (5%) of industry-owned patents that originated from industry research were the subject of JDs. In contrast, 32/41 (78%) patents owned by academia were the subject of JDs. Academia thus actively publishes through both modes of disclosure, whereas industry maintains relative secrecy by predominantly disclosing through PDs. Although a further 13/39 (33%) of industry-owned patents were published as JDs, these originated from academic or collaborative research. It is possible that some of the patented inventions not published in scientific journals may be published later on, because in a few instances we found a lag of up to four years between a priority filing and a JD.
Analysis of institution-type contribution to JDs was again deduced from the affiliations of authors (Fig. 2b) . Among the JDs we studied, Together, these comparisons indicate that we can consider the PMP disclosures to be a representative sample for biopharmaceutical disclosures. Hence, we judge that our results, using PMPs as a model, broadly represents biopharmaceuticals as a whole.
Disclosure trends by institution type
To identify the relative contribution of industrial or academic research to patented inventions, and consequently product development, we analyzed disclosure by institution type. Of the 95 patent families, 43% and 41% were owned by academic and industrial entities, respectively. The remaining 16% either were assigned to individuals or inventors or the assignee could not be ascertained from database information. Using inventor names from the PDs, we searched for JDs that corresponded to entries on the patent list to identify the institutional affiliation of named inventors.
Because not all PDs had a corresponding JD, we made certain assumptions: we assumed that all patents assigned to academia that did not have a corresponding JD had origins in academic research and that all patents assigned to industry without a corresponding JD originated from industry research. Using molecules used for diagnostic purposes. Nor are they necessarily restricted to product claims alone. The line in Figure 1a shows PCT biopharmaceutical filings by priority year. It, too, shows a decline or stagnation in filings (according to priority date) between 2002 and 2006, similar to the trend in PMP patenting.
An examination of PMP JDs from 2004 to 2007 reveals a largely static output (Fig. 1b,  bars) . In addition, for 2008, the year in which our study was done, extrapolating the number of PMP JDs that occurred before our cutoff date (n = 23 from January to July) to the full year suggests that PMP publication activity was similar to that in 2004 (n = 39), in keeping with the static output for [2004] [2005] [2006] [2007] .
To ascertain whether the temporal trends for PMP JDs are representative of the trends for biopharmaceuticals as a whole, we mined the PubMed database with the combined MeSH terms "Therapeutics" and "Recombinant Proteins" and excluded reviews. Over the period 2004-2007, the number of biopharmaceutical publications has also remained largely static, as shown by the line in Figure 1b . Thus the publication trend for the biopharmaceuticals as a whole generally reflects the static temporal trend for PMPs.
For this analysis we confined our searches to PMPs comprising recombinant protein molecules that have an intended therapeutic effect through systemic or topical administration, such as vaccines, monoclonal antibodies, hormones and immunomodulatory molecules. We excluded non-protein molecules, nutraceuticals, carrier and structural proteins such as gelatin and collagen, and disclosures that solely described enabling processes without describing, or claiming under the scope of their proprietary protection, one or more PMPs. We also disregarded patents with very broad claims to a variety of hosts that happened to include plants if supporting material in the specification for a plant expression claim was absent.
We searched the most recent five-year records of patent families claiming specific PMPs. A family of patents represents a set of applications filed locally and/or internationally that are united by a single priority date (the date of the earliest filed application, or priority application) and should therefore usually relate to the same core subject matter. In practice, because patent applications are usually published 18 months after filing, this meant coverage of patents for which the priority date of In practice, however, our subsequent results justify our choice of overlap period.
We stress here that all of our searches used very broad search queries and/or their corresponding patent codes, rather than narrower queries such as specific author names or names of molecules. An example would be the use of the queries "pharmaceutical" or "vaccine" rather than "osteoprotegrin" or "hepatitis C." This was done deliberately to avoid introducing selection bias toward one or more categories of information such as country of origin, molecule or institution type. For the same reasons we compiled and analyzed the patent and journal list independently, and avoided transferring the data derived from analysis of one list to the other, after performing JD-PD linked analyses as described later. For example, after retrieving by search a JD that corresponded to a particular entry on the PD list, we did not populate the JD list with the retrieval, even if it did not exist on the independently compiled JD list. Such retrievals were used only for specific analyses rather than to complement both lists. We studied the content of at least one member of a patent family, typically a Patent Cooperation Treaty (PCT) application, or the Derwent (DWPI) database-abstracted information for those Korean, Chinese and Japanese own-country applications that had no foreign relatives. Although we attempted to be exhaustive in our searches, there were some limitations; these include the sparse patent information in databases for some important economies, such as India. Therefore, in our comparative analyses of countries, we present only a selection of results.
Box 1 Scope of patent and journal searches
PAT e n T S of view and would therefore be consolidated into one JID. We thus consolidated the 211 JDs into 186 single JIDs. Next, we searched for patents corresponding to these JIDs, searching by author name and with queries related to the inventive concept to calculate the patent/ publication ratio (PPR) for each country and the EU. This ratio represents the proportion of JIDs for which a patent is sought; the higher the ratio, the greater the appetite of a country for patenting and commercialization. These ratios are shown in Figure 4 .
Korea had the highest PPR (80%), with the majority of JIDs also being the subject of PDs, followed by the United States, where 40% of JIDs were also filed as patents. Collectively the EU appeared to patent just under 20% of its JIDs, lagging significantly behind the United States and Korea. China, which had the highest number of consolidated JIDs after the United States and EU, had one of the smallest PPRs (4%).
Within these analyses, we found that most linkages fell within the temporal periods chosen for each disclosure type with very few outliers, vindicating our chosen PD-JD temporal overlap.
Patent office filing preferences
It is likely that the patent examination practices of different offices, in regard to both the willingness to grant an application and the assessment of patentability, may have an impact on the preferences of inventors or their institutions for filing at a particular office. The patent office filing preferences for the 240 members of the 95 families are shown in Figure 5 , also broken down into single-and multiple-office filings.
If one discounts exclusively single-member filings, which particularly skew the Korean data, the largest numbers of patents were filed with the US Patent and Trademark Office (USPTO), the Australian Patent Office (APO), the EPO and the Canadian Patent Office (CPO), in that order. The precedence of the APO over the member states as a whole. Though this is appropriate at the disclosure (publication) stage of a patent application, it should be noted that EPO patents are treated as individual national rights in their designated countries after grant.
It is clear that the majority of both types of disclosures come from US inventors and authors, more than for all EU states combined. Although European authors appear on comparable numbers of JDs to their counterparts in the United States, European inventors appear on far fewer PDs. Even so, when considered as a whole, only the EU represents meaningful competition to the United States. Korean inventors rank second in terms of appearance on PDs, but their authors rank only fourth in terms of JDs. They also make more disclosures through PDs than through JDs, though most of these are local-only filings by local inventors. If one ignores Korean patents, the United States clearly dwarfs all other single nations in disclosure volume.
Because patent applications are an indicator of a nation or region's appetite for product commercialization, it is possible to estimate commercial intent by quantifying the number of inventions published in papers that are patented. Expressed as a ratio, this will reflect the extent to which different nations attempt to commercialize inventions. And because the vast majority (95%) of JDs come from academic or academia-industry collaborative research (Fig. 2a) , this estimates in parallel the relative appetite for commercialization in the academic institutions of different nations.
To perform this analysis, we consolidated multiple JDs relating to a single inventive concept into units of one, which we defined as a journal inventive disclosure (JID). For example, a research group may publish two papers, one describing a PMP produced by a particular expression system and another describing a preclinical trial using the same PMP. These papers would be considered to have a unified inventive concept from a patenting point 182 of 209 (87%) were the product of academic scientists, 10 (5%) of industry scientists and 17 (8%) of academia-industry collaborationagain highlighting the reluctance of industry scientists to publish in scientific journals.
Disclosure trends by geographic location
A frequent practice in researching patent data to determine the geographical origin of inventions is to record the country of filing of a priority application (priority country). In both PDs and JDs, however, it is common for multiple institutions, sometimes from different countries, to be represented in a single disclosure. To be inclusive of all countries, in generating the data for Figure 3 we recorded the frequency of occurrence of all countries contributing to disclosures. Because of the centralized system of filings at the EPO-and the EU representing a united front in international economic competition-we present a cumulative figure for EU PAT e n T S the frontline of development, industry is likely to use patents more efficiently. Academia's main concern is often to generate licensing revenue, and academics and academic institutions may therefore let patents lapse if they cannot quickly find suitable licensees. Only more rarely will academics pursue a commercialization route via a startup or spinout company. However, industry patenting practices carry their own inefficiencies; for example, industry owns many patents that do not directly result in product development, but which may be maintained for other purposes such as competition control 12 .
Koreans disclose more via patents than in scientific journals (Fig. 3) , and as a result their inventors have larger patent volumes than those of any other single country with the exception of the United States. However, the majority of inventions by Koreans were filed in Korea only, indicating an intention to exploit only the local market. It is also likely that patents filed in the Korean language without translation are relatively cheap. All Korean JDs were from academia, and the majority of these were also the subject of patent disclosure, indicating that the Korean academic sector has a healthy commercial appetite.
The United States clearly leads in both types of disclosures. More importantly, the US academic sector has a twofold greater appetite for patenting than all the EU countries collectively, its main economic competitor (Fig. 4) . One reason for this may be that the Bayh-Dole Act is well established (dating from 1980), whereas the lag period before similar legislative instruments appeared in EU countries has meant that the EU has yet to catch up. Cultural attitudes among European academics may also play a significant role 13 . Access to venture capital, the main driver of academic start-ups and spinouts, may be another. Potential licensees for inventions are likely to be easier to find in the United States, encouraging more filings, and there is evidence that the majority of European universities earn little or no licensing revenue 14 . Unlike in the United States, the To overcome the problems of scale and accuracy, we focused on the role of disclosure through patent or journal documents in biopharmaceutical development, using the PMP sector as a model. It is well known that industry files patents in order to gain a monopoly position, attract investment, establish freedom to operate and commercialize products effectively; and therefore patents are a good indicator of intent to develop a product. The temporal trend for declining patenting activity (Fig. 1a) does not necessarily indicate that there is diminishing commercial interest in biopharmaceuticals. Indeed, with the drying up of the traditional pharmaceutical pipeline, the opposite may be true 5, 6 , and a report by Frost and Sullivan 7 makes an optimistic growth forecast for PMPs. Furthermore, a recent study shows that commercial success and numbers of products in development by biopharmaceutical firms have no clear correlation with the sizes of the firms' patent portfolios 8 . There was a reported 2.7% annualized decrease in PCT filings in the whole biotechnology arena in the period 2001-2005 (ref. 9) . It is likely that the decline in filings was more reflective of an increase in the quality of applications for biopharmaceuticals, as a consequence of both more stringent patentability criteria and diligent commercial assessment to warrant filing costs, coupled with a decrease in the indiscriminate and speculative volume filings of the past 10 .
Academia provides the bulk of enabling knowledge through research published in scientific journals (Fig. 2a) . It also has an important role in product development, as indicated by our finding that at least 64% of PMP patents are contributed to by academia (Fig. 2b) . This is supported by a recent report 11 showing that academic players have significant shares of patent volumes in many categories at all major patent offices.
One could argue that the proportion of patents owned by academia has limited direct correlation with product development. Being at EPO, and the large numbers filed at the CPO, were surprising given Australian and Canadian population and market sizes relative to the EU and their small numbers of patent disclosures (Fig. 3) .
We further examined the possibility that particular patent offices were relatively favorable destinations for foreign inventors seeking protection for PMPs, by looking at patent filings originating from foreign inventors at individual offices. The total number of foreign inventors filing in the USPTO was 18, comparable to a figure of 19 non-European inventors at the EPO. The majority of PMP applications at the APO and the CPO were filed by foreigners (n = 28 and n = 17, respectively). This gave proportions of foreign to total applications at these offices of 37% (USPTO), 73% (EPO), 93% (APO) and 85% (CPO). It is unsurprising that the patent office filings at the APO and CPO are largely foreign in origin. However, we were not expecting such a small proportion of the filings at the EPO to be from European inventorsdisproportionately lower than the percentage of their US counterparts filing at the USPTOespecially given the fact that European and US research activity is comparable in terms of JDs. The implications of this study are discussed collectively below.
Conclusions
A common method in researching patenting trends is to use patent codes in metasearches and compute the numbers of 'hits' . Although this method has value for very large data set in many fields of technology, it could lead to inaccuracies when studying biotechnology patents. This is because biotechnology patent documents usually comprise complex subject matter, extensive prior art, and claims ranging from the very broad to the very narrow. Consequently, on average they are the most voluminous patent documents 4 and are often classified under one or more codes that may not accurately reflect their content or claims. In our experience, initial searches produced results that were far less specific than journal searching. For these reasons, and because of the effort needed to correlate patents with journal disclosures, we chose a small field-PMPfor our study. An initial search using codes produced a broad list well in excess of 1,000 hits. Manual filtering of the list reduced this to 95 PMP patents with specific product claims, indicating that manual filtering is preferable for an accurate and focused study. Another potential limitation of some studies that report patent trends lies in their failure to explicitly state whether data consist of families or total volumes, leading to inaccurate conclusions. PAT e n T S considerations, coupled with our finding that Europe's academia has a relatively low appetite for patenting its biopharmaceutical research output, have important implications for both policymakers and scientists.
biotechnology inventions in the first place due to local patent examination practice. A recent online working paper 16 assessing pendency rates and outcomes at the USPTO, APO, EPO and JPO (Japanese Patent Office) revealed a number of interesting points. The average time taken to examine applications at the APO is 14 months, as compared to 42 months at the EPO, for a range of technologies surveyed. The APO grants a higher proportion of patents than the EPO. Within the EPO, a lower proportion of patents are granted for biotechnology than for other areas, marginally lower than even for software patents, a highly contentious area of patenting in Europe. Curiously, the study also notes that the EPO is "tough" on matched applications in biotechnology that have already been granted at the USPTO.
A healthy contribution to commerce via patenting is essential to sustain both industrial and academic-based biopharmaceutical research 13 , to generate licensing revenue and to bring essential goods to the market. Our results suggest that European scientists may not be as eager to protect their inventions as scientists elsewhere-a conclusion supported by a recent report on biotechnology patents 10 . Furthermore, given the size of the European market, the EPO does not seem to attract a corresponding share of patent filings. These absence of a grace period following a journal disclosure in European countries means a patent should be filed before or concurrently with submitting a paper. This may serve to dampen enthusiasm for patenting by the average academic-who often requires publication as a measure of success.
Although total patent filings were largest at the USPTO (Fig. 5) , the ratios of foreign to total filings at the APO, EPO and CPO were larger. It is possible that costs of patent attorneys in the United States are relatively high, and possibly prohibitive for many academic institutions elsewhere.
Given the size of the European marketcomparable to that of the United States-the EPO appears not to attract a commensurate share of patent filings. Also, although it attracts comparable numbers of applications from foreign applicants relative to the USPTO, the share of filings at the EPO by European applicants is lower than that for USPTO filings by US applicants. Furthermore, filings at the APO and CPO by foreigners, including European applicants, are surprisingly copious. There are a number of reasons for these apparent disparities. First, it is commonly perceived by the intellectual property fraternity in Europe that the EPO and national offices grant fewer biotechnology patents than do non-European developed nations-largely due to more stringent requirements relating to patentability. There is also a lack of uniform implementation and interpretation across nations of the EU Biotechnology Directive, which seeks to give greater protection to inventions that involve gene sequences 15 . These factors may deter filings by both Europeans and non-Europeans. For example, an academic institution in Europe would typically file a priority application in its own nation or EPO before assessing the commercial case for protection elsewhere, parallel to the filing preferences of European industry 4 . However, they may be deterred from filing many PAT e n T S
